PURPOSE: To compare the toxicity between hypofractionation vs. conventional fractionation schedules in patients with high-risk prostate cancer. METHODS AND MATERIALS: Between January 2003 and December 2007, 168 patients were randomized to receive either hypofractionated (62 Gy in 20 fractions within 5 weeks, 4 fractions/wk) or conventionally fractionated (80 Gy in 40 fractions within 8 weeks) three-dimensional conformal radiotherapy to the prostate and seminal vesicles. All patients had undergone a 9-month course of total androgen deprivation, with radiotherapy starting 2 months after initiation of the total androgen deprivation. RESULTS: The median follow-up was 32 and 35 months in the hypofractionation and conventional fractionation arms, respectively. For the patients developing acute toxicity, no difference between the two fractionation groups was found in either severity or duration of gastrointestinal or genitourinary toxicity. Also, no difference was found in the incidence and severity of late gastrointestinal and genitourinary toxicity between the two treatment schedules, with a 3-year rate of Grade 2 or greater toxicity of 17% and 16% for the hypofractionation arm and 14% and 11% for the conventional fractionation arm, respectively. A statistically significant correlation between acute and late gastrointestinal toxicity was found only in the conventional fractionation group. CONCLUSION: Our findings suggest that the hypofractionation regimen used in our study is safe, with only a slight, nonsignificant increase in tolerable and temporary acute toxicity compared with the conventional fractionation schedule. The severity and frequency of late complications was equivalent between the two treatment groups.
RCT Entities:
PURPOSE: To compare the toxicity between hypofractionation vs. conventional fractionation schedules in patients with high-risk prostate cancer. METHODS AND MATERIALS: Between January 2003 and December 2007, 168 patients were randomized to receive either hypofractionated (62 Gy in 20 fractions within 5 weeks, 4 fractions/wk) or conventionally fractionated (80 Gy in 40 fractions within 8 weeks) three-dimensional conformal radiotherapy to the prostate and seminal vesicles. All patients had undergone a 9-month course of total androgen deprivation, with radiotherapy starting 2 months after initiation of the total androgen deprivation. RESULTS: The median follow-up was 32 and 35 months in the hypofractionation and conventional fractionation arms, respectively. For the patients developing acute toxicity, no difference between the two fractionation groups was found in either severity or duration of gastrointestinal or genitourinary toxicity. Also, no difference was found in the incidence and severity of late gastrointestinal and genitourinary toxicity between the two treatment schedules, with a 3-year rate of Grade 2 or greater toxicity of 17% and 16% for the hypofractionation arm and 14% and 11% for the conventional fractionation arm, respectively. A statistically significant correlation between acute and late gastrointestinal toxicity was found only in the conventional fractionation group. CONCLUSION: Our findings suggest that the hypofractionation regimen used in our study is safe, with only a slight, nonsignificant increase in tolerable and temporary acute toxicity compared with the conventional fractionation schedule. The severity and frequency of late complications was equivalent between the two treatment groups.
Authors: C S Drodge; O Boychak; S Patel; N Usmani; J Amanie; M B Parliament; A Murtha; C Field; S Ghosh; N Pervez Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler Journal: J Clin Oncol Date: 2018-10-11 Impact factor: 44.544
Authors: Jeffrey V Brower; Jeffrey D Forman; Patrick A Kupelian; Daniel G Petereit; Vinai Gondi; Colleen A Lawton; Nick Anger; Sandeep Saha; Rick Chappell; Mark A Ritter Journal: Radiother Oncol Date: 2016-01-02 Impact factor: 6.280
Authors: C Franzese; A Fogliata; G R D'Agostino; L Di Brina; T Comito; P Navarria; L Cozzi; M Scorsetti Journal: J Cancer Res Clin Oncol Date: 2017-03-08 Impact factor: 4.553
Authors: Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den Journal: Cancer Treat Rev Date: 2013-03-01 Impact factor: 12.111
Authors: Stefan Höcht; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Tobias Hölscher; Thomas Martin; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel Journal: Strahlenther Onkol Date: 2016-09-14 Impact factor: 3.621